LeMaitre Vascular, Inc. (LMAT) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $107.10 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole- and limited-source suppliers.
LeMaitre Vascular develops and markets vascular medical devices and human tissue cryopreservation services for peripheral vascular disease and cardiovascular procedures. Approximately 95% of net sales go through a direct sales force of 160 reps across North America, Europe, and... Read more
Sell if holding. Analyst target reached at $107.10 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole- and limited-source suppliers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole- and limited-source suppliers10-K Item 1A: 'We rely on sole- and limited-source suppliers for many of our important components and certain products, including our VascuCel and CardioCel biologic patch, Artegraft biologic vascular graft and Omniflow biosynthetic vascular graft.'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02LOWDirector Bridget Ross not standing for re-election at 2026 Annual Meeting; no disagreement. David Roberts nominated as Class II director; Roberts will conditionally resign as Class I director upon election to rebalance board classes.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $107.10 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole- and limited-source suppliers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $102.33. Score 5.3/10, moderate confidence.
Take-profit target: $115.65 (+8.0% upside). Prior stop was $102.33. Stop-loss: $102.33.
Concentration risk — Supplier: sole- and limited-source suppliers; Analyst target reached - limited upside remaining; Earnings in 5 days (event risk).
LeMaitre Vascular, Inc. trades at a P/E of 42.6 (forward 33.7). TrendMatrix value score: 3.0/10. Verdict: Sell.
16 analysts cover LMAT with a consensus score of 4.0/5. Average price target: $111.
What does LeMaitre Vascular, Inc. do?LeMaitre Vascular develops and markets vascular medical devices and human tissue cryopreservation services for...
LeMaitre Vascular develops and markets vascular medical devices and human tissue cryopreservation services for peripheral vascular disease and cardiovascular procedures. Approximately 95% of net sales go through a direct sales force of 160 reps across North America, Europe, and Asia Pacific.